Journal · Clinical therapeutics · Updated 21 November 2026
Advances in Therapy
Read Advances in Therapy articles on DeepDyve. No university library needed.
Advances in Therapy has published research on medical treatment since 1984, covering therapies, diagnosis and patient care across many areas of clinical medicine. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Advances in Therapy at a glance
- Full title
- Advances in Therapy
- Abbreviation (NLM)
- Adv Ther
- Publisher
- Springer Nature
- Print ISSN
- 0741-238X
- Online ISSN (eISSN)
- 1865-8652
- First published
- 1984
- Subjects
- Therapeutics
- Access model
- Hybrid (87% free to read in 2026)
Ways to access Advances in Therapy
87% of the articles Advances in Therapy published from January 1 to November 18, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 87% of Advances in Therapy articles published from January 1 to November 18, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Advances in Therapy. Check its journal list and whether it offers remote access.
- DeepDyve. Read Advances in Therapy articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Advances in Therapy’s 2025 Journal Impact Factor is 4.7, and its 5-year Impact Factor is 4.6.
4.7
Journal Impact Factor (2025)
4.6
5-year Impact Factor (2025)
2 days
Median time to first decision
3.5M
Downloads (2025)
Source: journal metrics on the Advances in Therapy homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Advances in Therapy research worth reading
Published March to May 2026. Summaries describe what the authors report.
-
Comparative Effectiveness and Safety of Fecal Microbiota Transplantation in Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis
In a systematic review and meta-analysis of 16 randomized controlled trials in ulcerative colitis, Huang and colleagues report that fecal microbiota transplantation improved clinical remission (RR = 1.81, 95% CI: 1.41–2.31) and that adverse events did not differ from control.
Huang et al. · Advances in Therapy, published online April 7, 2026 · DOI 10.1007/s12325-025-03431-0
-
Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study
Zisman and colleagues report preliminary PHINDER results in 190 participants with interstitial lung disease, 105 (55%) of whom had precapillary pulmonary hypertension, and say their findings support combining pulmonary function testing, lung imaging and echocardiography to improve early detection.
Zisman et al. · Advances in Therapy, published online March 10, 2026 · DOI 10.1007/s12325-026-03508-4
-
Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey
In a survey of 550 US adults using injectable semaglutide for weight management, the authors report that the median recalled Food Noise Questionnaire score fell from 13 before treatment to 6 after starting it.
Arnaut et al. · Advances in Therapy, published online May 30, 2026 · DOI 10.1007/s12325-026-03636-x
-
Cognitive Decline and Illness Progression in Bipolar Disorder
In a systematic review of adults with bipolar disorder, Ji and colleagues report that cross-sectional studies suggest more mood episodes or longer illness duration are associated with poorer cognition, while several longitudinal studies reported no significant cognitive change over time relative to healthy controls.
Ji et al. · Advances in Therapy, published online March 2, 2026 · DOI 10.1007/s12325-026-03527-1
-
First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study
In the China subgroup of the randomized phase 3 KEYNOTE-966 study, Ren and colleagues report median overall survival of 14.1 months with pembrolizumab plus gemcitabine and cisplatin versus 9.9 months with placebo plus chemotherapy (HR, 0.74; 95% CI, 0.51–1.08), with no new safety signals.
Ren et al. · Advances in Therapy, published online May 23, 2026 · DOI 10.1007/s12325-026-03578-4
Related journals
Questions about Advances in Therapy
How can I read Advances in Therapy articles without a subscription?
87% of Advances in Therapy articles published from January 1 to November 18, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Advances in Therapy articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Advances in Therapy?
Advances in Therapy’s NLM (PubMed) abbreviation is Adv Ther.
What is the ISSN of Advances in Therapy?
The print ISSN is 0741-238X and the online ISSN is 1865-8652.
What is the impact factor of Advances in Therapy?
Advances in Therapy’s Journal Impact Factor is 4.7 (2025), and its 5-year Impact Factor is 4.6, according to Springer Nature’s published metrics.
Is Advances in Therapy open access?
Advances in Therapy is a hybrid journal: authors can choose to publish open access or under the subscription model. From January 1 to November 18, 2026, 325 of 374 Advances in Therapy articles (87%) carry a Creative Commons license, per Crossref.
Advances in Therapy articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.
Start reading Advances in Therapy today
One month free, then less than $2 a day. Advances in Therapy, plus millions of articles from thousands of journals.






